Laser Diagnostic Technologies
LDT invented and commercialized a new standard for glaucoma detection with its proprietary ocular nerve fiber measurement instrument.
Launch date
Market cap
CAD7.5b
Enterprise valuation
CAD7.6b (Public information from Sep 2024)
Share price
€59.8 AFX.F
San Diego California (HQ)
Financials
Estimates*
EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Revenues | 1.3b | 1.6b | 1.9b | 2.1b | 1.9b | 2.1b |
% growth | - | 23 % | 16 % | 10 % | (9 %) | 11 % |
EBITDA | 267m | 410m | 483m | 502m | - | - |
% EBITDA margin | 20 % | 25 % | 25 % | 24 % | - | - |
Profit | 122m | 236m | 294m | 290m | - | - |
% profit margin | 9 % | 14 % | 15 % | 14 % | - | - |
R&D budget | 219m | 232m | 291m | 349m | - | - |
R&D % of revenue | 16 % | 14 % | 15 % | 17 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | Acquisition | |
Total Funding | - |